Article

Creation of "humanized" mice to study human immunity.

Diabetes Division, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Current protocols in immunology / edited by John E. Coligan ... [et al.] 06/2008; Chapter 15:Unit 15.21. DOI: 10.1002/0471142735.im1521s81
Source: PubMed

ABSTRACT "Humanized" mice are a promising translational model for studying human hematopoiesis and immunity. Their utility has been enhanced by the development of new stocks of immunodeficient hosts, most notably mouse strains such as NOD-scid IL2rgamma(null) mice that lack the IL-2 receptor common gamma chain. These stocks of mice lack adaptive immune function, display multiple defects in innate immunity, and support heightened levels of human hematolymphoid engraftment. Humanized mice can support studies in many areas of immunology, including autoimmunity, transplantation, infectious diseases, and cancer. These models are particularly valuable in experimentation where there is no appropriate small animal model of the human disease, as in the case of certain viral infections. This unit details the creation of humanized mice by engraftment of immunodeficient mice with hematopoietic stem cells or peripheral blood mononuclear cells, provides methods for evaluating engraftment, and discusses considerations for choosing the appropriate model system to meet specific goals.

2 Followers
 · 
104 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To develop an animal model of injury that more closely represents the human inflammatory cell response to injury. Because the mouse inflammatory response to burn injury cannot account for the contribution of human-specific genes, animal models are needed to more closely recapitulate the human inflammatory response and improve the translational impact of injury research. To this end, we hypothesized that the human inflammatory cell response to injury could be selectively assessed after severe burn injury using humanized mice. NOD-Scid-IL2Rγ mice were transplanted with human hematopoietic CD34 progenitor cells; their engraftment confirmed and then subjected to 30% total body surface area steam burn injury. Blood, bone marrow, and lung tissue were collected 4 hours after injury and human inflammatory cell mobilization analyzed using flow cytometry and immunohistochemistry. Burn injury caused mobilization of human inflammatory cells into the systemic circulation. Next, the burn injury was accompanied by evidence of histologic lung injury and concomitant mobilization of human CD45 immune cells into the lung that were associated with increased trafficking of human CD11b myeloid cells. These experiments are the first to demonstrate the suitability of humanized mice for injury research. They offer the possibility to address very specific research questions that are not amenable to traditional mouse models of injury, for example, the emerging role of certain human-specific genes that are either unrepresented or totally absent, from the mouse genome.
    Annals of Surgery 11/2014; DOI:10.1097/SLA.0000000000001123 · 7.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since their description and identification in leukemias and solid tumors, cancer stem cells (CSC) have been the subject of intensive research in translational oncology. Indeed, recent advances have led to the identification of CSC markers, CSC targets, and the preclinical and clinical evaluation of the CSC-eradicating (curative) potential of various drugs. However, although diverse CSC markers and targets have been identified, several questions remain, such as the origin and evolution of CSC, mechanisms underlying resistance of CSC against various targeted drugs, and the biochemical basis and function of stroma cell-CSC interactions in the so-called ‘stem cell niche.’ Additional aspects that have to be taken into account when considering CSC elimination as primary treatment-goal are the genomic plasticity and extensive subclone formation of CSC. Notably, various cell fractions with different combinations of molecular aberrations and varying proliferative potential may display CSC function in a given neoplasm, and the related molecular complexity of the genome in CSC subsets is considered to contribute essentially to disease evolution and acquired drug resistance. In the current article, we discuss new developments in the field of CSC research and whether these new concepts can be exploited in clinical practice in the future.
    Journal of Hematology & Oncology 02/2015; 8. DOI:10.1186/s13045-015-0113-9 · 4.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The distinct nature of Acute Lymphoblastic Leukemia (ALL) in adults, evidenced by inferior treatment outcome and different genetic landscape, mandates specific studies of disease initiating mechanisms. In this study we used NOD/LtSz-scid IL2Rγ null(c) (NSG) mouse xenotransplantation approaches to elucidate leukemia-initiating cell (LIC) biology in primary adult precursor B (pre-B) ALL in order to optimise disease modelling. In contrast with xenografting studies of pediatric ALL, we found modification of the NSG host environment using preconditioning total body irradiation (TBI) was indispensable for efficient engraftment of adult non t(4;11) pre B ALL whereas t(4;11) pre-B ALL was successfully reconstituted without this adaptation. Furthermore, TBI based xenotransplantation of non t(4;11) pre-B ALL enabled detection of a high frequency of LIC's (<1:6900) and permitted frank leukemic engraftment from a remission sample containing drug resistant Minimal Residual Disease. Investigation of TBI sensitive SDF-1/CXCR4 signaling revealed greater functional dependence of non t(4;11) pre-B ALL on this niche based interaction providing a possible basis for the differential engraftment behavior. Thus, our studies establish the optimal conditions for experimental modelling of human adult pre-B ALL and demonstrate the critical pro-tumorogenic role of microenvironment derived SDF-1 in regulating adult pre-B LIC activity that may present a therapeutic opportunity.
    Blood 05/2014; 124(1). DOI:10.1182/blood-2014-01-549352 · 9.78 Impact Factor

Preview

Download
0 Downloads
Available from